Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients: A Case Report and Literature Review-Reference-Cited by-同舟云学术

Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients: A Case Report and Literature Review

Published:2024-01-10 Issue: Volume: Page:1-6
ISSN:0927-3948
Container-title:Ocular Immunology and Inflammation
language:en
Short-container-title:Ocular Immunology and Inflammation

Author:

Mendez Rafael¹^ORCID,Pineda-Sierra Juan Sebastián²^ORCID,Romero-Santos Sofia²^ORCID,Cifuentes-González Carlos²³^ORCID,Bonaccorso Silvina⁴,Couto Cristobal⁵,Schlaen Ariel⁵^ORCID,Mejía-Salgado Germán²³^ORCID,de-la-Torre Alejandra²³^ORCID

Affiliation:

1. Ophthalmology Department, Hospital Universitario San Ignacio, Facultad de Medicina, Pontificia Universidad Javeriana, Bogota, Colombia

2. Ophthalmology Interest Group, Neuroscience (NEUROS) Research Group, Neurovitae Research Center, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia

3. Neuroscience (NEUROS) Research Group, Neurovitae Research Center, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia

4. Hematology Department, Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

5. Uveitis Section, Ophthalmology Department, Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Funder

no funding

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/09273948.2023.2295540

Reference16 articles.

1. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

2. Drug-induced uveitis: A review

4. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial